-

Satellos to Present at the Stifel 2023 Healthcare Conference

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Stifel 2023 Healthcare Conference taking place November 14 and 15 in New York City.

Mr. Frank Gleeson, Co-founder and CEO of Satellos, will provide a corporate presentation on Tuesday November 14, 2023, at 1:15 p.m. ET and will participate in one-on-one meetings during the conference along with Ms. Elizabeth Williams, CFO of Satellos. To access a webcast of the panel presentation live or for 90 days after the event, please click here.

About Satellos Bioscience Inc.

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead drug candidate is an oral, small molecule in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contacts

Investors: Liz Williams, ir@satellos.com
Business Development: Ryan Mitchell, Ph.D., bd@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091

Satellos Bioscience Inc.

TSX VENTURE:MSCL

Release Versions

Contacts

Investors: Liz Williams, ir@satellos.com
Business Development: Ryan Mitchell, Ph.D., bd@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091

More News From Satellos Bioscience Inc.

Satellos Bioscience Shareholders Elect Two New Board Members

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. “I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,” said Frank Gleeson, Satellos co-founder and CEO. “We...

Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held June 18, 2025 (the “Meeting”). Satellos is pleased to announce that all the nominees listed in the management information circular dated May 12, 2025 (the “Circular”), were elect...

Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to impr...
Back to Newsroom